- Home
- AIRT vs STTK Comparison
AIRT vs STTK Comparison
Compare AIRT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- STTK
- Stock Information
- Founded
- AIRT 1980
- STTK 2016
- Country
- AIRT United States
- STTK United States
- Employees
- AIRT N/A
- STTK N/A
- Industry
- AIRT Air Freight/Delivery Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- STTK Health Care
- Exchange
- AIRT Nasdaq
- STTK Nasdaq
- Market Cap
- AIRT 55.5M
- STTK 56.8M
- IPO Year
- AIRT N/A
- STTK 2020
- Fundamental
- Price
- AIRT $19.96
- STTK $1.37
- Analyst Decision
- AIRT
- STTK Hold
- Analyst Count
- AIRT 0
- STTK 3
- Target Price
- AIRT N/A
- STTK $2.00
- AVG Volume (30 Days)
- AIRT 4.3K
- STTK 131.9K
- Earning Date
- AIRT 02-12-2025
- STTK 03-03-2025
- Dividend Yield
- AIRT N/A
- STTK N/A
- EPS Growth
- AIRT N/A
- STTK N/A
- EPS
- AIRT N/A
- STTK N/A
- Revenue
- AIRT $298,215,000.00
- STTK $6,435,000.00
- Revenue This Year
- AIRT N/A
- STTK $313.04
- Revenue Next Year
- AIRT N/A
- STTK N/A
- P/E Ratio
- AIRT N/A
- STTK N/A
- Revenue Growth
- AIRT 3.36
- STTK 382.75
- 52 Week Low
- AIRT $14.85
- STTK $0.94
- 52 Week High
- AIRT $30.60
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- AIRT 49.95
- STTK 60.23
- Support Level
- AIRT $19.55
- STTK $1.21
- Resistance Level
- AIRT $20.69
- STTK $1.36
- Average True Range (ATR)
- AIRT 0.46
- STTK 0.10
- MACD
- AIRT -0.03
- STTK 0.01
- Stochastic Oscillator
- AIRT 47.48
- STTK 90.00
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.